Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Exclusion Criteria

• •Are pregnant and/or lactating
• •Diagnosis of any chronic pain syndrome that would interfere with the assessment of PHN
• •evidence of multiple causes of neuropathic pain,e.g.lumbar radiculopathy in the lumbosacral area
• •Have had neuroablation or neurosurgical intervention for PHN
• •Have been taking opioid analgesics for \>5 days/week
• •Have received nerve block or intrathecal analgesia within 6 weeks of the study
• •History of significant gastrointestinal disease, liver disease, renal disease, endocrine disease, or cardiovascular disease
• •clinically significant abnormal clinical laboratory test results or vital signs
• •Are immunocompromised or immunosuppressed for any reason
• •History of alcohol or other substance abuse (not including nicotine or tobacco) within 5 years
• •Significant psychiatric disorder which requires drug treatment (except depression or anxiety treated with Selective Serotonin Re-uptake Inhibitors)
• •Have received an investigational drug or have used an investigational device within 30 days of Screening.
• •Have previously been randomized to this study